8-K: Shuttle Pharma Regains Nasdaq Compliance Post-Equity Raise

Shuttle Pharmaceuticals Holdings, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a $2.5 million private placement.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported stockholders' equity of $1,394,161 as of September 30, 2025.
• This figure was below the Nasdaq Capital Market's minimum requirement of $2,500,000 for continued listing (Listing Rule 5550(b)(1)).
• The company believes it has regained compliance as of November 17, 2025, due to a private placement.
• The private placement, consummated on November 4, 2025, raised approximately $2.5 million in aggregate gross proceeds.
• Nasdaq Listing Qualifications staff will continue to monitor the company's compliance.
• Failure to evidence compliance in the next periodic report could lead to delisting.

Sentiment

Score: 6

Explanation: While the company successfully addressed a critical delisting threat, the underlying issue of insufficient stockholders' equity and the need for an emergency capital raise indicate ongoing financial fragility. The resolution is positive, but the situation itself highlights vulnerabilities.

Positives

• The company believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement.
• A private placement on November 4, 2025, raised approximately $2.5 million in gross proceeds, addressing the equity shortfall.

Negatives

• The company was previously not in compliance with Nasdaq Listing Rule 5550(b)(1), having stockholders' equity of $1,394,161 against a required $2,500,000 as of September 30, 2025.
• Continued monitoring by Nasdaq staff means future non-compliance could still lead to delisting.

Risks

• Volatility in the market price of the company's common stock.
• Ability to manage costs and execute on operational and budget plans.
• Risks related to general market, economic, and other conditions.
• Ability to maintain the listing of its common stock on Nasdaq.
• Other risks included in periodic reports and other filings with the U.S. Securities and Exchange Commission.

Future Outlook

The company expresses its belief that it has regained compliance with Nasdaq's stockholders' equity requirement following a recent private placement. However, Nasdaq staff will continue to monitor compliance, and failure to evidence compliance in the next periodic report could result in delisting. The company acknowledges various risks that could cause actual results to differ from forward-looking statements.

Management Comments

• The Company believes that, as of the date of this Current Report on Form 8-K, it has regained compliance with the Stockholders Equity Requirement based upon the Companys private placement consummated on November 4, 2025, pursuant to which the Company raised aggregate gross proceeds of approximately $2.5 million, before deducting placement agent fees and offering expenses payable by the Company.

Industry Context

This filing primarily addresses a specific regulatory compliance issue related to Nasdaq listing requirements, rather than broader industry trends. Maintaining listing on a major exchange like Nasdaq is crucial for biotechnology companies like Shuttle Pharmaceuticals to access capital markets and maintain investor visibility, which is a common challenge for smaller, development-stage firms.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The successful capital raise and regaining of Nasdaq compliance mitigate the immediate risk of delisting, which would have severely impacted share liquidity and value. However, the private placement likely involved dilution.
• Investors: Provides clarity on the company's listing status and financial stability, albeit after a period of non-compliance.
• Regulatory Authorities: Nasdaq will continue to monitor the company's compliance.

Next Steps

• Nasdaq Listing Qualifications staff will continue to monitor the company's ongoing compliance with the Stockholders Equity Requirement.
• The company must evidence compliance in its next periodic report to avoid potential delisting.

Key Dates

Recommendation

The company successfully addressed an immediate delisting threat by raising capital, which is a positive for maintaining market access and liquidity. However, the need for such a raise to meet basic listing requirements indicates underlying financial weakness. While the immediate crisis is averted, the company remains under Nasdaq scrutiny, and future financial performance will be key. Investors should hold to observe sustained compliance and operational improvements rather than buying into a potentially fragile recovery, or selling given the immediate threat has been mitigated.

Keywords

Shuttle Pharmaceuticals, SHPH, Nasdaq Compliance, Stockholders Equity, Private Placement, Delisting Risk, Capital Raise, Biotechnology, Pharmaceuticals